Clinical trials: Eyes With Retinal Disease
X-linked Retinoschisis
Safety and Efficacy of rAAV-hRS1 in Patients With X-linked Retinoschisis (XLRS)
This study will evaluate the safety and efficacy of a recombinant adeno-associated virus vector expressing retinoschisin (rAAV2tYF-CB-hRS1) in patients with X-linked retinoschisis.
- Trial name
- NCT02416622
- Testing
- rAAV2tYF-CB-hRS1
- Where
- 9 sites in United States
- Volunteers
- 27 people
- Sponsor
- Beacon Therapeutics
Macular Degeneration
Safety and Pharmacokinetics of Abicipar Pegol Intravitreal Injections in Japanese Patients With Neovascular AMD
This study will evaluate the safety and to characterize the systemic pharmacokinetics of free and vascular endothelial growth factor (VEGF)-bound abicipar following multiple monthly intravitreal injections of abicipar in Japanese…
- Trial name
- PINE (NCT03335852)
- Testing
- Abicipar pegol
- Where
- 5 sites in Japan
- Volunteers
- 11 people
- Sponsor
- Allergan
Neovascular (Wet) Age-Related Macular Degeneration
Safety, Tolerability, and Efficacy of Aflibercept in Patients With Neovascular Age-Related Macular Degeneration
The primary objectives of the study are to determine the safety of high-dose aflibercept (hereafter referred to as HD) and to determine if HD provides greater intraocular pharmacodynamic (PD) effect and/or longer duration of…
- Trial name
- CANDELA (NCT04126317)
- Testing
- aflibercept, High-dose aflibercept
- Where
- 46 sites in United States, Puerto Rico
- Volunteers
- 106 people
- Sponsor
- Regeneron Pharmaceuticals
Retinitis Pigmentosa
Intravitreal Injection of SeeQ CdSe 655 Alt Nanoparticles for Patients With Degenerative Retinal Diseases
This study was a prospective, open label feasibility study conducted at a single clinical site (APEC, Mexico City) to evaluate the safety and preliminary effectiveness of the SeeQ device, with each patient's serving as his/her…
- Trial name
- NCT04008771
- Testing
- SeeQ CdSe 655 ALT
- Where
- Mexico
- Volunteers
- 20 people
- Sponsor
- 2C Tech Corp
Macular Degeneration, Age-Related Macular Degeneration
A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002)
Researchers are looking for new ways to treat neovascular age-related macular degeneration (NVAMD). Available standard (usual) treatments for NVAMD, such as aflibercept, may not work for every person.
- Conditions
- Macular Degeneration, Age-Related Macular Degeneration, Choroidal Neovascularization, Wet Macular Degeneration
- Trial name
- MALBEC (NCT07440225)
- Testing
- Tiespectus, Aflibercept
- Where
- 132 sites in United States, Argentina and 10 more
- Volunteers
- 960 people
- Sponsor
- EyeBiotech Ltd.
Macular Degeneration
A Study of MSI-1256F (Squalamine Lactate) To Treat "Wet" Age-Related Macular Degeneration
Age-Related Macular Degeneration (AMD) is a degenerative eye disease of the retina that causes a progressive loss of central vision. AMD is the leading cause of legal blindness among adults age 50 or older in the Western world.
- Trial name
- NCT00333476
- Testing
- MSI-1256F (Squalamine Lactate)
- Where
- 9 sites in United States
- Volunteers
- 140 people
- Sponsor
- Genaera Corporation
Geographic Atrophy Secondary to Age-related Macular Degeneration
Study to Evaluate a Pegcetacoplan (Syfovre®) Prefilled Syringe
This is a phase 3, open-label study to evaluate the safety of pegcetacoplan in a prefilled syringe (PFS)
- Trial name
- NCT07214740
- Testing
- APL-2, Pegcetacoplan
- Where
- 5 sites in United States
- Volunteers
- 44 people
- Sponsor
- Apellis Pharmaceuticals, Inc.
Neovascular Age-Related Macular Degeneration
Safety and Efficacy of LX102 Gene Therapy in Patients With Neovascular Age-related Macular Degeneration (nAMD) (VENUS)
The goal of this study is to evaluate the overall safety and efficacy of LX102 gene therapy for nAMD.
- Trial name
- NCT06196840
- Testing
- LX102 subretinal injection, Aflibercept intravitreal injection
- Where
- 11 sites in China
- Volunteers
- 50 people
- Sponsor
- Innostellar Biotherapeutics Co.,Ltd
Retinitis Pigmentosa, Retinal Diseases
Dose-Escalation Study to Evaluate the Safety and Tolerability of Intravitreal vMCO-I in Patients With Advanced Retinitis Pigmentosa
The purpose of the study is to evaluate the safety and tolerability of a single intravitreal injection of virally-carried Multi-Characteristic Opsin I (vMCO-I)
- Conditions
- Retinitis Pigmentosa, Retinal Diseases, Retinal Degeneration
- Trial name
- NCT04919473
- Testing
- Gene Therapy product:vMCO-I
- Where
- India
- Volunteers
- 11 people
- Sponsor
- Nanoscope Therapeutics Inc.
Age-related Macular Degeneration
Telescope Exchange Study
VisionCare's Implantable Miniature Telescope (IMT, intraocular telescope or telescope) is indicated for monocular implantation to improve vision in eyes of patients at least 65 years of age with severe to profound vision…
- Trial name
- TES (NCT03011554)
- Testing
- Implantable Miniature Telescope (IMT)
- Where
- 14 sites in United States
- Volunteers
- 75 people
- Sponsor
- VisionCare, Inc.
Diabetic Macular Edema, Visual Impairment
A 12-month, Randomized, Efficacy and Safety Study of 0.5 mg Ranibizumab vs Laser in Chinese Diabetic Macular Edema (DME) Patients
Study of efficacy and safety of 0.5 mg ranibizumab in Chinese patients with diabetic macular edema (DME)
- Trial name
- REFINE (NCT02259088)
- Testing
- Ranibizumab (RFB002), Laser
- Where
- 28 sites in China
- Volunteers
- 384 people
- Sponsor
- Novartis Pharmaceuticals
Wet Macular Degeneration
The Impact of Baseline Visual Acuity on the Treatment Outcomes in Patients Treated With AflIbercept in Real-life Clinical Setting
The study will assess the mean change in Visual Acuity (VA) (overall and stratified by baseline VA) at year 1 and 2 of treatment with Aflibercept in real-life setting.
- Trial name
- INSIGHT (NCT03278262)
- Testing
- Aflibercept (Eylea, BAY86-5321)
- Where
- Sweden
- Volunteers
- 2,312 people
- Sponsor
- Bayer
Neovascular Age-related Macular Degeneration, Retinal Vein Occlusion
A Study to Understand the Usage of an Artificial Intelligence Technology Called DARWEN for Eye Disorders and to Find Out the Factors Influencing Treatment Frequencies in People With nAMD and RVO
This is an observational study in which data already collected from people with the eye disorders below are studied. In observational studies, only observations are made without participants receiving any advice or any changes to…
- Trial name
- AIRSPEED (NCT06495203)
- Testing
- anti-VEGF treatment
- Where
- Canada
- Volunteers
- 1,350 people
- Sponsor
- Bayer
Retinal Drusen, Age-related Macular Degeneration
Evaluation of a New Eye-specific Multivitamin Formula in Participants at Risk of Age-related Macular Degeneration (AMD)
The aim of this study is to evaluate the clinical benefits in visual function from dietary supplementation of the Lumega-Z carotenoid liquid-supplement in participants with drusen and at risk of AMD.
- Conditions
- Retinal Drusen, Age-related Macular Degeneration, Macular Degeneration
- Trial name
- AMD (NCT03946085)
- Testing
- Lumega-Z, AREDS2
- Where
- United States
- Volunteers
- 79 people, healthy volunteers welcome
- Sponsor
- Guardion Health Sciences, Inc.
Cytomegalovirus Retinitis, HIV Infections
A Randomized Study Comparing the Safety and Efficacy of Two Regimens of Oral Ganciclovir to Intravenous Ganciclovir Maintenance Therapy for Cytomegalovirus Retinitis in People With AIDS Who Have Received Prior Ganciclovir Therapy
To compare the safety and tolerance of oral ganciclovir at a double dose 3 times/day or a single dose 6 times/day to IV ganciclovir given for 20 weeks of maintenance therapy.
- Trial name
- NCT00002247
- Testing
- Ganciclovir
- Where
- 20 sites in United States, Canada
- Volunteers
- 225 people
- Sponsor
- Hoffmann-La Roche
Age-Related Macular Degeneration
A Pilot Study of the Safety of MC-1101 in Both Normal Volunteers and Patients With Early Dry AMD
The safety and comfort of repeated administrations of a topically-administered ophthalmic formulation of MC-1101 will be established through investigator assessments and subject reporting over a 3 day period.
- Trial name
- NCT01013376
- Testing
- MC-1101, Vehicle
- Where
- United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- MacuCLEAR, Inc.
Macular Edema, Diabetic
A Phase 2, Multi-Center Study To Compare The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist With Ranibizumab In Adults With Diabetic Macular Edema
The study hypothesis under test is that administration of the CCR2/5 antagonist has the potential to be as effective as the current treatment options for subjects with diabetic macular edema.
- Trial name
- NCT01994291
- Testing
- Ranibizumab, PF-04634817
- Where
- 63 sites in United States, Bulgaria and 7 more
- Volunteers
- 199 people
- Sponsor
- Pfizer
Age-related Macular Degeneration, Choroidal Neovascular Age-related Macular Degeneration
Association of Macular Pigment Optical Density (MPOD) and Genetic Variants in Complement Factor H in Subjects With Choroidal Neovascular (CNV)
Subjects with wet AMD, dry AMD, and age-matched controls will undergo routine occular measurements, will provide a blood and cheek cell sample, and will have macular pigment optical density (MPOD) measured to determine if there…
- Trial name
- NCT01682382
- Where
- United States
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Sequenom, Inc.
Macular Degeneration, Geographic Atrophy
A Prospective Observational Study to Assess the Reliability and Validity of the MLSDT
The goal of this observational study is to assess the reliability and validity of the 9-object MLSDT for evaluation of participants with moderate to severe vision impairment when tested without a wearable low-vision magnifying…
- Conditions
- Macular Degeneration, Geographic Atrophy, Stargardt Disease
- Trial name
- NCT06805474
- Testing
- Observational
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Nanoscope Therapeutics Inc.
Anti- VGF Inhibitor, Diabetic Macular Edema
Study To Evaluate Safety And Tolerability Of Pegaptanib Sodium In Patients With Diabetic Macular Edema
This study will asses sthe safety of pegaptanib sodium in patients with diabetic macular edema. The hypothesis is that pegaptanib is safe and efficacious in patients with diabetic macular edema.
- Conditions
- Anti- VGF Inhibitor, Diabetic Macular Edema, Diabetic Retinopathy
- Trial name
- NCT01189461
- Testing
- pegaptanib sodium
- Where
- 12 sites in Finland, Spain and 2 more
- Volunteers
- 46 people
- Sponsor
- Pfizer